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Abstract 
Purpose: To understand the role of Bcl-2 overexpression in oral tongue squamous cell carcinoma (OTSCC) patients 
and investigate the efficacy of targeting Bcl-2 in OTSCC.
Methods: The expression level of Bcl-2 on normal tongue cells and OTSCC cells were measured by real-time PCR and 
western blotting. The functional roles of Bcl-2 were examined by MTS, flow cytometry and xenograft cancer mouse 
model. Mechanism studies were performed by analyzing mitochondrial functions in a panel of OTSCC cell lines.
Results: Bcl-2 is up-regulated at mRNA and protein levels in a panel of OTSCC cell lines compared to normal tongue 
epithelial cells (NTEC). Importantly, overexpression of Bcl-2 confers resistance of OTSCC cells to chemotherapeutic 
drug cisplatin treatment. Overexpression of Bcl-2 in NTEC significantly increased cell growth. In contrast, inhibition of 
Bcl-2 by genetic and pharmacological approaches inhibits proliferation and induces apoptosis in OTSCC cells. Mecha-
nistically, Bcl-2 inhibitor ABT-199 impairs mitochondrial functions as shown by the decreased levels of mitochondrial 
membrane potential, mitochondrial respiration and ATP, and the increased levels of ROS in OTSCC cells. In addition, 
ABT-199 inhibits proliferation and induces apoptosis and mitochondrial dysfunctions in NTEC cells, but to a less extent 
than in OTSCC cells. We further show that ABT-199 augments the effects of cisplatin in eliminating OTSCC cells in 
in vitro tongue cancer cellular system and in vivo tongue cancer xenograft mouse model.
Conclusions: Inhibition of Bcl-2 effectively targets OTSCC cells through inhibiting proliferation and inducing apopto-
sis. Inhibition of Bcl-2 also augments the inhibitory effects of cisplatin in vitro and in vivo.
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Background
The clinical management of the majority of the oral can-
cer patients are still challenge with the 5-year overall sur-
vival and disease-free survival remaining ~55 and ~60 % 
(Goldstein et al. 2013). Oral tongue squamous cell carci-
noma (OTSCC) is a subtype of oral cancer, which is more 
clinically aggressive with rapid local invasion and a high 
recurrence rate (Tan et al. 2012). OTSCC has increased 
incidence over the last several years and poor progno-
sis (Garnaes et al. 2015). Current treatment for OTSCC 
include surgery (using microvascular reconstructive 
techniques), radiotherapy (e.g. external beam radiother-
apy and brachytherapy), chemotherapy (e.g. cisplatin) 
and various combinations of these modalities depend-
ing on the disease stages and presentations (Ferlay et al. 
2015; Shiboski et  al. 2005; Huang and O’Sullivan 2013; 
Andreadis et  al. 2003). The molecular pathogenesis of 
OTSCC and its underlying mechanisms to chemotherapy 
resistance are not well understood. Research have found 
that epigenetic and genetic factors, such as oncogenes 
(e.g. Ras) and tumor suppressor genes (e.g. p53), can sig-
nificantly influence the development of OTSCC (Khan 
and Bisen 2013; Murugan et  al. 2012). It is therefore 
important to elucidate the mechanisms involved in the 
resistance and identify effective targets for patients with 
OTSCC.
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Activation of pro-survival B cell lymphoma 2 (BCL2) 
family genes (e.g. MCL1, BCL2 and BCLX) is common 
hallmark of cancer and contributes to tumorigenesis 
via BCL2-mediated apoptosis (Adams and Cory 2007). 
BCL-2 is transcriptionally up-regulated in response to 
cytokines or pathways involved in proliferation, such as 
PI3K/AKT and Ras (Kinoshita et  al. 1995; Franke et  al. 
2003). Downregulation of Bcl-2 by using ABT-199, a 
potent and selective inhibitor of Bcl-2 (Souers et  al. 
2013), has been shown to inhibit growth of a panel of 
cancers (Ko et al. 2014; Goff et al. 2013). Several studies 
have been shown that the expression of Bcl-2 family pro-
teins are associated with clinical stage, histologic grade 
and poor prognosis in OTSCC patients (Camisasca et al. 
2009; de Vicente et  al. 2006; Zhang et  al. 2012). How-
ever, little is known about the functional roles of Bcl-2 in 
OTSCC.
In this study, we investigated the expression and roles 
of Bcl-2 in normal tongue cells and multiple OTSCC 
cell lines. Our results show that Bcl-2 is up-regulated in 
OTSCC compared to normal tongue cells. The up-regu-
lation of Bcl-2 contributes to the resistance of OTSCC to 
chemotherapeutic drug treatment. We further show the 
essential roles of Bcl-2 in growth and survival of OTSCC 
cells. In addition, Bcl-2 inhibition effectively inhibits pro-
liferation and induces apoptosis of OTSCC via impairing 
mitochondrial functions. Finally, we demonstrate that the 
combination of BCL-2 inhibitor ABT-199 and chemo-
therapeutic drug cisplatin are more effective than single 
drug alone in targeting OTSCC both in vitro and in vivo.
Methods
Cell culture and drugs
Human primary cultured normal tongue epithelial cells 
(NTEC, a kind gift from Dr. Sun’s laboratory and Dr. 
Zeng’s laboratory) (Wen et  al. 2014; Song et  al. 2006) 
were maintained in keratinocyte/serum-free medium 
(Invitrogen Life Technologies, US). Oral tongue squa-
mous cell carcinoma (OTSCC) cell lines SCC-9 and SCC-
25 were purchased from the American Type Culture 
Collection. Tca8113 and CAL27 were purchased from the 
Committee of the Type Culture Collection of the Chinese 
Academy of Sciences. Cells were cultured in RPMI 1640 
medium supplemented with 10  % fetal bovine serum 
(HyClone, UK). ABT-199 (Catalogue No. CT-A199) and 
cisplatin (Catalogue No. 479306) were purchased from 
ChemieTek and Sigma, respectively.
Plasmid and siRNA transfection
For Bcl-2 overexpression, OTSCC cell lines were trans-
fected with 1.5  µg pEMD or pEMD-Bcl2 plasmids (a 
kind gift from Clark Distelhorst) as previously described 
(Wang et al. 2001). BCL-2 knockdown were carried out 
in TSCC lines by transfecting with 100  nM scramble 
siRNA or human BCL-2-specific siRNAs using Dharma-
fect Transfection Reagent (Dharmacon RNAi Technolo-
gies) according to manufacture’s instructions. The target 
sequences of human BCL-2-specific are siRNA BCL-2: 
AAC ATC GCC CTG TGG ATG ACT.
Western blotting
Cellular protein were extracted by RIPA lysis buffer 
(50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1 % Nonidet P-40, 1 mM Na3VO4, 1 mM NaF, and 1× 
protease inhibitor, Life Technologies Inc, US). Total pro-
tein content was measured using the bicinchoninic acid 
protein assay kit (Thermo Scientific, US). Equal amount 
of proteins were resolved using denaturing sodium dode-
cyl sulphate–polyacrylamide gel electrophoresis and ana-
lysed by western blot using antibodies against BCL-2 and 
β-catenin (Cell Signalling Technologies, US).
Real‑time PCR analysis
The total RNA of NTEC, SCC-25, SCC-9, CAL27 and 
Tca8113 cells were isolated by using TRIzol Reagent (Life 
technologies, CA, US). The cDNA was amplified using 
a SsoFast EvaGreen Supermix kit (Bio-rad. CA) and real 
time PCR analysis was then performed using CFX96 RT 
PCR system (Bio-rad, CA). The primers are for human 
BCL-2 (5′-CTG CAC CTG ACG CCC TTC ACC-3′ and 
5′-CAC ATG ACC CCA CCG AAC TCA AAG A-3′) and 
β-actin (5′-AAG GAT TCC TAT GTG GGC GAC G-3′ 
and 5′-GCC TGG ATA GCA ACG TAC ATG G-3′).
Measurement of proliferation and apoptosis
Cells were treated with ABT-199, cisplatin or combina-
tion for 3 days. Proliferation activity was measured by the 
CellTiter 96R AQueous One Solution Cell Proliferation 
assay kit (Promega, US). To monitor cell density, 1 × 105 
cells were seeded on Day 1. The cell density were counted 
daily for 4  days under microscope. We determined the 
cell density by using Trypan Blue staining and then 
hemocytometer. Briefly, we take the average cell count 
from each of the sets of 16 corner squares and multiply 
by 10,000; then multiply by 2 to correct for the 1:2 dilu-
tion from the Trypan Blue addition.
Apoptotic cells were stained with Annexin V-FITC 
(Beckman Coulter, France) and analysed on a Beckman 
Coulter. The percentage of Annexin V-positive cells was 
determined by using CXP software.
Determination of mitochondrial membrane potential, 
oxygen consumption rate (OCR), reactive oxygen species 
(ROS) and cellular ATP level
Cells were treated with ABT-199 for 24 h. For mitochon-
drial membrane potential measurement, the cells were 
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incubated with 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethyl 
benzimidazolylcarbocyanine iodide (JC-1, Invitrogen) for 
30 min prior to PBS washing. Labelled cells were resus-
pended in 500 µL PBS and flow cytometry was conducted 
on a Beckman Coulter FC500. The mitochondrial mem-
brane potential level was analysed using FlowJo version 
7.7.1 (TreeStar, Ashland, OR). OCR was measured using a 
Seahorse XF24 extracellular flux analyser (Seahorse Bio-
science, US) as per manufacturer’s instructions (Varum 
et  al. 2011). Cells in 24-well-plate were equilibrated to 
the un-buffered medium in a CO2-free incubator and 
then transferred to the Seahorse XF24 extracellular flux 
analyser for OCR measurement. To measure ROS levels, 
cells were stained with redox-sensitive probe Carboxy-
H2DCFDA in PBS buffer. Labelled cells were re-sus-
pended in PI buffer and the level of Carboxy-H2DCFDA 
was measured using Beckman Coulter FC500. ATP levels 
were measured by CellTiter-Glo Luminescent Cell Viabil-
ity Assay (Promega, WI, US) according to the manufac-
turer’s instructions.
Tongue cancer xenograft in SCID mouse
SCID mice were purchased from Animal Resources 
Centre Australia. All of the animal experiments were 
approved by the Institutional Animal Care and Use 
Committee of Yangtze University. The SCID mice were 
inoculated with 1 million SCC-9 cells subcutaneously in 
the flank. The inoculation volume (0.2  ml) comprised a 
50:50 mixture of cells in growth media and Matrigel (BD 
Biosciences). Tumour length and width were measured 
every 3 days and tumor volume was estimated by apply-
ing the following equation: volume = length × width2/2. 
When tumors reached approximately 200 mm3, the mice 
were treated with vehicle control, oral cisplatin at 20 mg/
kg, oral ABT-199 20  mg/kg or combination of both for 
30 days. Tumor frozen section slides were fixed with 4 % 
paraformaldehyde (Sigma, US). The nuclei and cytoplasm 
were counterstained with hematoxylin and eosin (H&E). 
The tumor sections were observed under a confocal 
microscopy (Zeiss LSM 510, Germany).
Statistical analyses
All data are expressed as mean ± SD. A non-parametric 
Student’s t test was performed using the two-tailed dis-
tribution. A p value <0.05 was considered statistically 
significant.
Results
BCL‑2 is activated and confers resistance 
to chemotherapeutic drug treatment in tongue squamous 
carcinoma cells
To understand the roles of BCL-2 in OTSCC cells, we 
investigated the expression levels of BCL-2 in multiple 
OTSCC cell lines and normal tongue epithelial cells 
(NTEC). Consistent with the previous studies de Vicente 
et al. (2006) and Mallick et al. (2009), we found that both 
mRNA and protein expression levels of BCL-2 were sig-
nificantly increased in all tested OTSCC cell lines com-
pared to NTEC (Fig. 1a, b; Additional file 1: Figure S1). 
Among four OTSCC cell lines, BCL-2 expression is high-
est in Tca8113 and lowest in CAL27. Compared to paren-
tal NTEC cells, we further found that there is a significant 
increase in proliferation in NTEC cells with BCL-2 over-
expression (Fig.  1c, d), suggesting the role of BCL-2 in 
cell growth. Notably, chemotherapeutic drug cisplatin 
at 5 µM is less effectively in inhibiting proliferation and 
inducing apoptosis in OTSCC cell lines with high Bcl-2 
expression (e.g. Tca8113) than OTSCC cell lines with 
low Bcl-2 expression (e.g. CAL27) (Fig. 1e, f ). These data 
demonstrates that Bcl-2 activation confers resistance to 
chemotherapy drug treatment in OTSCC.
BCL‑2 inhibition by genetic and pharmacological 
approaches inhibits proliferation and induces apoptosis 
of OTSCC cells
To further understand the role of Bcl-2 in OTSCC cells, 
we depleted BCL-2 in several OTSCC cell lines with 
BCL-2-specific siRNA and investigated their growth 
and survival. Western blot analysis showed that Bcl-2 
expression levels were significantly decreased by BCL-2 
siRNA but not scrambled control siRNA (Fig. 2a; Addi-
tional file  1: Figure S2). We observed that depletion of 
BCL-2 led to decreased growth and increased apoptosis 
compared to control cells (Fig.  2b, c). Consistently, we 
treated OTSCC cell lines with 0.5, 1 and 5 µM of ABT-
199, a selective and potent BCL-2 inhibitor (Souers et al. 
2013) and observed that ABT-199 dose-dependently 
inhibited proliferation and induced apoptosis of OTSCC 
cell lines (Fig. 2d, e; Additional file 1: Figure S3). In addi-
tion, it seems that Tca8113 cells are more sensitive to 
BCL-2 inhibition than CAL27 cells (Fig.  2b–e). We fur-
ther found that ABT-199 at 1 and 5 but not 0.5 µM sig-
nificantly inhibits proliferation and induces apoptosis 
of NTEC cells (Fig.  3), suggesting that ABT-199 targets 
NTEC cells to a less extent than OTSCC cells. Taken 
together, these data demonstrate that BCL-2 is important 
for OTSCC cell growth and survival. 
BCL‑2 inhibition impairs mitochondrial functions 
in OTSCCs
 As Bcl-2 resides upstream of irreversible cellular dam-
age and plays a vital role in mitochondrial functions 
(Gross et al. 1999), we next examined the mitochondrial 
membrane potential, oxygen consumption rate, lev-
els of ROS and ATP in OTSCC cells exposed to ABT-
199. We found that ABT-199 decreased mitochondrial 
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membrane potential and mitochondrial respiration 
(as indicated by OCR) in a dose-dependent manner in 
multiple OTSCC cell lines (Fig.  4a, b). Consistent with 
decreased mitochondrial membrane potential and respi-
ration, the increased ROS and decreased ATP levels were 
also observed in OTSCC cell lines exposed to ABT-199 
(Fig.  4c, d). ABT-199 also induces mitochondrial dys-
functions in NTEC cells as shown by the decreased mem-
brane potential, OCR, ATP levels and increased ROS 
levels, but to a less extent than in OTSCC cells (Fig. 5). 
These data show that Bcl-2 inhibition impairs mitochon-
drial functions in OTSCC as well as NTEC cells. 
Bcl‑2 inhibitor significantly enhances the inhibitory effects 
of chemotherapeutic drug cisplatin in vitro and in vivo
We have shown that Bcl-2 inhibition is active against 
OTSCC cells (Fig.  2). We next investigated whether its 
combination with tongue cancer chemotherapy drug cis-
platin resulted in greater efficacy than single drug alone. 
We found that combination of ABT-199 (0.5  µM) and 
cisplatin (1 µM) induces significantly much more apopto-
sis than single drug alone in SCC-9, SCC-25, CAL27 and 
Tca8113 cells (Fig. 6).
We evaluated the ability of combination to suppress 
tumor growth in vivo in tongue squamous tumor xeno-
graft established in immunocompromised mice. After a 
single oral dose of 20 mg per kg body weight in xenograft 
derived from SCC-9 cells, ABT-199 and cisplatin caused 
a tumor growth inhibition of ~30 and ~40  %, respec-
tively (Fig.  7a). However, when ABT-199 was combined 
with cisplatin, approximately 100 % tumor growth inhibi-
tion was observed throughout the duration of treatment 
(Fig.  7a). Consistently, H&E staining showed a marked 
increase in individual neoplastic cell death (indicated 
Fig. 1 BCL-2 is up-regulated and confers resistance to cisplatin in OTSCC cells. a mRNA and b protein levels of BCL-2 in normal tongue epithelial 
cell (NTEC) and OTSCC cell lines. c Protein levels of Bcl-2 after Bcl-2 transfection (pEMD-Bcl2) in NTEC cells. d Overexpression of Bcl-2 promotes 
NTEC growth. Cells are electroporated with 1.5 μg pEMD, or pEMD-Bcl2 and cultured for 48 h prior to WB and monitoring growth. Different inhibi-
tory effects of cisplatin on the proliferation (e) and survival (f) in SCC-25, SCC-9, CAL27 and Tca3188 cells. Cisplatin at 5 µM was used. Data were 
presented as mean ± SD. *p < 0.05
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by cytoplasmic swelling/vacuolization/disintegration) 
in the combination treatment group as compared to the 
control and single drug treatment groups (Fig. 7b). These 
results were in concordance with our in  vitro data, and 
confirmed that ABT-199 enhances the inhibitory effects 
of cisplatin in OTSCC.
Discussion
OTSCC is an aggressive subtype of oral cancer and is 
resistant to current chemotherapy. Although several 
clinical studies have shown that Bcl-2 expression is asso-
ciated with neck lymph node metastasis and poor prog-
nosis in oral cancer (Camisasca et al. 2009; Mallick et al. 
2009; Popovic et  al. 2007), the functional roles of Bcl-2 
in OTSCC and whether it is involved in the resistance 
of OTSCC to chemotherapy are not well understood. In 
this work, we are the first to demonstrate that Bcl-2 is 
overexpressed and plays essential roles in the growth and 
survival of OTSCC cells. Importantly, up-regulation of 
Bcl-2 confers resistance of OTSCC cells to chemothera-
peutic drug treatment. In addition, Bcl-2 inhibition effec-
tively targets OTSCC cells via impairing mitochondrial 
functions and augments cisplatin’s effects in eliminating 
OTSCC cells.
Our data that the BCL-2 mRNA and protein levels 
are significantly increased in multiple OTSCC cell lines 
Fig. 2 BCL-2 inhibition inhibits proliferation and induces apoptosis of OTSCC cells. a Bcl-2 protein expression level on BCL-2 knockdown by siRNA in 
SCC-25, SCC-9, CAL27 and Tca3188 cells. b Proliferation is decreased and c apoptosis is increased in Bcl-2 depleted OTSCCs. Cells are electroporated 
with 100 nM siRNA control or siRNA BCL-2 and cultured for 48 h prior to WB, proliferation and apoptosis assays. ABT-199 inhibits proliferation (d) and 
induces apoptosis (e) of OTSCCs in a dose-dependent manner. Data were presented as mean ± SD. *p < 0.05
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compared to normal tongue epithelial cells (Fig.  1a, 
b) are consistent with the previous study that Bcl-2 is 
overexpressed in primary OTSCC tissues (Popovic et al. 
2007). We further extend the previous studies by dem-
onstrating that Bcl-2 up-regulation contributes resist-
ance of OTSCC cells to cisplatin treatment (Fig.  1e, f ) 
and combination of BCL-2 selective inhibitor ABT-199 
and cisplatin is more effective in eliminating OTSCC 
cells (Fig.  6). The combination of ABT-199 and cispl-
atin is superior to single drug alone and completely 
arrests OTSCC in  vivo tumor growth (Fig.  7). Taken 
together, our study clearly demonstrates the therapeutic 
value of targeting BCL-2 in overcoming chemotherapy 
resistance in OTSCC. Compared to other BCL-2 fam-
ily inhibitors (e.g. navitoclax), ABT-199 has shown effi-
cacy with less antiplatelet activity and a more favorable 
therapeutic index in patients with refractory chronic 
myeloid leukemia (Souers et al. 2013). In lines with the 
earlier publications, our work suggests that ABT-199 is 
a useful addition to the treatment armamentarium for 
OTSCC.
We further demonstrate that Bcl-2 overexpression 
in normal tongue epithelial cells promotes the growth 
(Fig.  1c, d). In contrast, knockdown BCL-2 by using 
siRNA or inhibition of its activity by using ABT-199 
inhibits proliferation and induces apoptosis of OTSCC 
cells (Fig. 2). Activation of pro-survival BCL-2 has been 
shown to play positive roles in survival in various tumors 
(Adams and Cory 2007; Domen et  al. 1998; Jiang and 
Milner 2003). In agreement with this notion, we are the 
first to show the protective and supportive roles of Bcl-2 
on growth and survival in OTSCC.
Fig. 3 The effects of BCL-2 inhibitor ABT-199 on NTEC cells. ABT-199 at 1 and 5 µM significantly inhibits proliferation (a) and induces apoptosis (b) of 
NTEC cells. ABT-199 at 0.5 µM has no significant inhibitory effects in NTEC cells. Data were presented as mean ± SD. *p < 0.05
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A consequence of Bcl-2 inhibition is the mitochondrial 
dysfunction as demonstrated by the decreased mito-
chondrial membrane potential, decreased mitochondrial 
respiration and decreased ATP levels, and the increased 
ROS levels in OTSCC cells treated with selective Bcl-2 
inhibitor ABT-199 (Fig.  4). This finding supports the 
previous study that BCL-2 inhibition targets oxidative 
phosphorylation in leukemia stem cells (Lagadinou et al. 
2013). Besides mitochondrial respiration inhibition, our 
study extends the previous work by demonstrating that 
inhibition of Bcl-2 decreases mitochondrial membrane 
potential, inhibits ATP production and induces ROS 
generation. Targeting mitochondrial metabolism has 
emerged as an attractive therapeutic strategy in cancer 
due to their unique dependence on proper mitochondrial 
functions (Vander Heiden 2011; Jaras and Ebert 2011; 
Mayevsky 2009; Hagland et al. 2007). Our work suggests 
that targeting mitochondria may be an alternative thera-
peutic strategy in OTSCC.
In conclusion, our work on the identification of essen-
tial roles of BCL-2 in OTSCC provides better under-
standing of the molecular mechanisms underlying 
Fig. 4 Bcl-2 inhibitor impairs mitochondrial functions in OTSCCs. a ABT-199 decreases mitochondrial membrane potential in SCC-25, SCC-9, CAL27 
and Tca3188 cells. Cells were stained with JC-1 dye prior to flow cytometry. b ABT-199 dose-dependently inhibits mitochondrial respiration. OCR 
was measured using a Seahorse XF24 extracellular flux analyser in the absence of compound injection. ABT-199 increases ROS (c) and decreases ATP 
(d) levels in OTSCCs. Cells were treated with ABT-199 for 24 h prior to mitochondrial function assays. Data were presented as mean ± SD. *p < 0.05
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Fig. 5 Bcl-2 inhibitor impairs mitochondrial functions in NTEC cells. ABT-199 at 1 and 5 µM decreases mitochondrial membrane potential (a), mito-
chondrial respiration (b), increases ROS (c) and decreases ATP (d) levels in NTEC cells. Data were presented as mean ± SD. *p < 0.05
Fig. 6 Bcl-2 inhibitor augments the inhibitory effects of cisplatin in tongue cancer cells in vitro. Combination of ABT-199 and cisplatin is superior in 
inducing apoptosis than single drug alone. The concentrations of ABT-199 and cisplatin used in combination studies are 0.5 and 1 µM, respectively. 
Data were presented as mean ± SEM. *p < 0.05, compared to single arm treatment
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resistance of OTSCC cells to chemotherapy. Our work 
also suggests a rationale for targeting BCL-2 and mito-
chondria in OTSCC treatment.
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